Chemoradiotherapy for locally advanced rectal cancer

Abstract

Long Cheng, Li Guoquan, Jiang Yongmei, Yi Tienan, Sun Qiushi. Chemoradiotherapy for locally advanced rectal cancer[J]. Journal of International Oncology, 2015, 42(7): 545-547.

［1］ Quirke P, Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRCCR07 and NCICCTGCO16 randomized clinical trial［J］. Lancet, 2009, 373(9666): 821-828. ［2］ Greto D, Paiar F, Saieva C, et al. Neoadjuvant oxaliplatin and 5fluorouracil with concurrent radiotherapy in patients with locally advanced rectal cancer: a singleinstitution experience［J］. Radiol Med, 2013, 118(4): 570-582. ［3］ Fitzgerald TL, Biswas T, O′Brien K, et al. Neoadjuvant radiotherapy for rectal cancer: adherence to evidencebased guidelines in clinical practice［J］. World J Surg, 2013, 37(3): 639-645. ［4］ Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials［J］. Lancet, 2001, 358 (9290): 1291-304. ［5］ Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for highrisk rectal carcinoma［J］. N Engl J Med, 1991, 324(11): 709-715. ［6］冯瑞, 李明焕, 于金明. 158例Ⅱ和Ⅲ期直肠癌根治术后不同治疗方法疗效分析［J］. 中华放射肿瘤学杂志, 2009, 18(3): 224-225. ［7］ Tulchinsky H, Shmueli E, Figer A, et al. An interval>7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and diseasefree survival in patients with locally advanced rectal cancer［J］. Ann Surg Oncol, 2008, 15(10): 2661-2667. ［8］ Lim SB, Choih S, Jeong SY, et al. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers［J］. Ann Surg, 2008, 248 (2): 243-251. ［9］ Samuelian JM, Callister MD, Ashman JB, et al. Reduced acute bowel toxicity in patients treated with intensitymodulated radiotherapy for rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2012, 82 (5): 1981-1987. ［10］ Jabbour SK, Patel S, Herman JM, et al. Intensitymodulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits［J］. Int J Surg Oncol, 2012, 82(5): 1-7. ［11］ Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomized, multicentre, noninferiority, phase 3 trial［J］. Lancet Oncol, 2012, 13(6): 579-588. ［12］ Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR01 randomized phase Ⅲ trial［J］. J Clin Oncol, 2011, 29(20): 2773-2780. ［13］ Gérard JP, Azria D, GourgouBourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase Ⅲ trial ACCORD 12/0405Prodige 2［J］. J Clin Oncol, 2010, 28(10): 1638-1644. ［14］ Gérard JP, Azria D, GourgouBourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer［J］. J Clin Oncol, 2012, 30(36): 4558-4565. ［15］ Rdel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locallyadvanced rectal cancer: initial results of the German CAO/ARO/AIO04 randomised phase 3 trial［J］. Lancet Oncol, 2012, 13(7): 679-687. ［16］ Hong YS, Kim DY, Lim SB, et al. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: longterm results of a Phase Ⅱ study［J］. Int J Radiat Oncol Biol Phys, 2011, 79(4): 1171-1178. ［17］ Gollins S, Sun Myint A, Haylock B, et al. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imagingdefined locally advanced rectal cancer: impact on longterm clinical outcomes［J］. J Clin Oncol, 2011, 29(8): 1042-1049. ［18］ Erben P, Strbel P, Horisberger K, et al. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximabbased chemoradiotherapy in locally advanced rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2011, 81(4): 1032-1038. ［19］ Kim SY, Shim EK, Yeo HY, et al. Kras mutation statusand clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase Ⅱ trials［J］. Int J Radiat Oncol Biol Phys, 2013, 85(1): 201-207. ［20］ Dewdney A, Cunningham D, Taberbero J, et al. Multicenter randomized phase Ⅱ clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with highrisk rectal cancer(EXPERTC)［J］. J Clin Oncol, 2012, 30(14): 1620-1627. ［21］ Willett CG, Duda DG, Ancukiewicz M, et al. Asafety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase Ⅰ/Ⅱ study compared with standard chemoradiation in locally advanced rectal cancer［J］. Oncologist, 2010, 15(8): 845-851. ［22］ Nogué M, Salud A, Vicente P, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabinebased chemoradiotherapy in magnetic resonance imaging defined poorprognosis locally advanced rectal cancer: the AVACROSS study［J］. Oncologist, 2011, 16(5): 614-620. ［23］ Dipetrillo T, Pricolo V, Lagaresgarcia J, et al. Neoadjuvant bevacizumab, oxaliplatin, 5fluorouracil, and radiation for rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2012, 82(1): 124-129.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[6]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[7]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[8]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[9]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42.
[10]	Cui Tenglu, Lyu lu, Sun Pengfei.Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 548-552.
[11]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474.
[12]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[13]	Lyu Lu, Sun Pengfei.Gut flora and cervical cancer[J]. Journal of International Oncology, 2023, 50(6): 373-376.
[14]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing.Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer[J]. Journal of International Oncology, 2023, 50(5): 268-273.
[15]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association.Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version）[J]. Journal of International Oncology, 2023, 50(4): 193-201.

Chemoradiotherapy for locally advanced rectal cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments